Dear editor,

In a recent study published in *Critical Care*, Fernando SM and colleagues investigated the impact of new-onset atrial fibrillation (NOAF) on clinical outcomes in critically ill patients \[[@CR1]\]. They performed univariate analysis and found that the length of stays (LOS) in ICU and hospital was both longer in the NOAF group versus non-NOAF group. They then concluded that NOAF was associated with increased LOS in ICU and increased total costs. While the conclusion appeared intuitive and statistically sound, it could be the result of immortal time bias. Immortal time is a span of cohort follow-up during which, because of exposure definition, the outcome under study could not occur \[[@CR2]\]. The NOAF can happen at any time during ICU stay and patients live longer in the ICU can have more chance to report NOAF. For example, a patient can have NOAF on day 4 and the outcome such as ICU discharge or death cannot happen before day 4. In this situation, the period from days 1 to 3 are considered as immortal time because if the outcome happens during the period, the patient cannot experience NOAF. The immortal time is incorrectly attributed to the exposure of NOAF, but actually, the NOAF do not contribute to the survival time. The same applies to the mortality outcome. The authors used binary logistic regression model to adjust for confounding effect and found there was no independent association of NOAF and mortality \[[@CR3]\]. The truth could be that NOAF is associated with increased mortality risk, but since patients who lived longer can have more chances to experience NOAF, the neural effect reported in the paper was actually the result of the true adverse effect and the bias towards beneficial effect. Potential solutions to control for the immortal time bias are as follows: (1) perform analysis by restricting to patients who had NOAF on day 1 and compare to those without NOAF, (2) consider the time of NOAF and include NOAF as time-varying covariate in the Cox proportional hazard model \[[@CR4]\], and (3) perform time-dependent propensity score matching by including covariates that can influence the onset of NOAF \[[@CR5]\].

This comment refers to the article available at 10.1186/s13054-020-2730-0.
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The authors would like to thank Drs. Lu and Chen for their comments on our recent article related to outcomes and costs associated with new-onset atrial fibrillation (NOAF) in critically ill adults \[[@CR1]\]. Drs. Lu and Chen suggest caution in the interpretation of our study results, particularly as they relate to the length of stay and costs, due to the possibility of immortal time bias. Indeed, the use of time-dependent covariates (such as NOAF) has the potential to confound multivariate models \[[@CR2]\]. However, as seen in our original study, the majority of patients who developed NOAF did so on the first day of hospital admission, consistent with previous studies in this population \[[@CR6], [@CR7]\]. As suggested by Drs. Lu and Chen, we conducted sensitivity analyses of our data, restricting the NOAF population to only those who developed NOAF on the first day of hospital admission (*n* = 962, 62.4% of the original NOAF population). Indeed, our original results persist, with patients with developing NOAF on the first day of admission still experiencing prolonged hospital stay, as compared to patients who did not develop NOAF (Table [1](#Tab1){ref-type="table"}). We similarly repeated our generalized linear model restricted to this select population, in order to determine if NOAF was still associated with total hospital costs (Table [2](#Tab2){ref-type="table"}). We found that NOAF was indeed a predictor of total hospital costs, even when only considering patients who developed NOAF on the first day of admission. These findings support the notion that our results were not markedly influenced by immortal time bias. Table 1Outcomes of ICU patients with new-onset atrial fibrillation (NOAF) on the first day of admission and those without NOAFCharacteristicNew-onset atrial fibrillation on day 1 (*n* = 962)No atrial fibrillation (*n* = 13,473)Adjusted odds ratio^c^ (95% CI)*P* valueIn-hospital mortality, *n* (%)367 (38.1)4034 (29.9)1.03 (0.95--1.11)0.34Persistent atrial fibrillation, *n* (%)^b^238 (24.7)--ICU length of stay, days, median (IQR)7 (2--14)6 (2--9)\< 0.01Hospital length of stay, days, median (IQR)14 (6--27)12 (4--25)\< 0.001Ventilator-free days, median (IQR)6 (2--8)6 (4--10)0.08*Abbreviations: ICU* intensive care unit, *IQR* interquartile range^a^Only includes patients surviving to discharge^b^Defined as the presence of any atrial fibrillation following 24 h of treatment^c^Ratio of NOAF to patients with no atrial fibrillation Table 2Generalized linear model with gamma distribution and log link for the total cost for patients with new-onset atrial fibrillation (NOAF) on the first day or admission and those without NOAF (*n* = 14,435)VariableCost ratio95% CI*P* valueAge (per 5 years)0.960.90--1.030.07Male gender1.010.88--1.120.17New-onset atrial fibrillation1.081.02--1.19\< 0.01MODS (per 1 point)0.960.91--0.98\< 0.01Comorbidities Congestive heart failure0.960.87--1.060.35 Peripheral vascular disease1.050.97--1.130.22 Hypertension1.020.92--1.090.66 Chronic obstructive pulmonary disease0.950.88--1.120.59 Diabetes mellitus1.020.92--1.110.47 Chronic kidney disease0.980.81--1.210.42 Liver disease0.910.77--1.080.31 Alcohol misuse1.020.95--1.080.77Elixhauser comorbidity score (per 1 point)0.990.90--1.070.53No CPR directive at ICU admission0.820.70--0.92\< 0.001Location prior to ICU admission Emergency departmentRef Hospital wards1.040.87--1.200.51 Operating room1.090.99--1.290.06 Peripheral hospital0.930.79--1.060.11Most responsible diagnosis OtherRef Infection/sepsis1.060.89--1.200.45 Respiratory failure1.911.29--2.41\< 0.001 Trauma1.491.15--1.88\< 0.001 Malignancy0.940.79--1.100.38 Spontaneous intracranial hemorrhage2.191.71--2.60\< 0.001 Stroke1.141.01--1.280.04 Overdose/poisoning0.880.80--0.96\< 0.01 Renal failure0.830.66--0.93\< 0.001 Gastrointestinal bleeding1.120.97--1.200.10 Congestive heart failure1.060.95--1.150.39 Cardiac arrest1.130.89--1.230.68 Seizures/status epilepticus1.191.01--1.400.03 Diabetic ketoacidosis0.730.61--0.83\< 0.001In-hospital death0.630.56--0.69\< 0.001Length of stay (per 1 day)1.031.02--1.05\< 0.01Invasive mechanical ventilation1.251.16--1.35\< 0.001Renal replacement therapy1.091.02--1.14\< 0.01*Abbreviations: MODS* Multiple Organ Dysfunction Score, *ICU* intensive care unit, *CI* confidence interval, *CPR* cardiopulmonary resuscitation

Finally, we would like to clarify that total hospital costs are not inferred as a multiple of hospital length of stay, as Drs. Lu and Chen suggest. In fact, all direct costs are linked directly to the patient identification number, and while they may be associated with length of stay (e.g., a person who stays in hospital for a longer length of time is likely to have increased testing and therapies, translating to higher costs), they are not obtained through a multiplication of length of stay, but rather reflect the direct resource use for each individual patient \[[@CR8]\].
